688091.SH
上海谊众
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 36.96
−7.65%Year over year
Reported trailing growth
- Revenue
- +84.4%
- EBITDA
- —
- EBIT
- +846.1%
- EPS
- +1614.7%
- Free cash flow
- -12.9%
- Operating cash flow
- +240.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +10.2%
- EBITDA
- -21.5%
- EBIT
- -25.7%
- Net income
- -23.3%
- EPS
- -31.4%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026